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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2014, KaohsiuAbstract The aim of this study was to investigate the role of 2-fluorine-18-fluoro-2-deoxy-D-
glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in the initial
staging and prediction of bone marrow involvement in patients with newly diagnosed lym-
phoma. A total of 185 patients with newly diagnosed lymphoma were enrolled. All patients
received PET/CT and bone marrow biopsy as part of a staging work-up. At the initial staging,
17 patients (9.2%) with occult nodal or extranodal lesions were upstaged after a review of the
PET/CT studies. PET/CT was found to be useful in the differentiation of aggressive lymphoma
subtypes from the indolent subtype based on higher standardized uptake value (SUV) (16.67 vs.
7.98, p < 0.001). The results of bone marrow biopsy and PET/CT in the detection of bone
marrow involvement were concordant in 152 patients (82.1%); positive concordance was
observed in 21 patients, and negative concordance was observed in 131 patients. A high
concordance rate was found between aggressive B cell lymphoma and Hodgkin’s lymphoma
(88.1% and 93.8%, respectively). High negative predictive values (NPVs) for excluding bone
marrow involvement were observed in aggressive B-cell lymphoma (93.2%) and Hodgkin’s lym-
phoma (100%). Diffuse bone marrow FDG uptake accurately predicted bone marrow in aggres-
sive B-cell lymphoma with a positive predictive value (PPV) of 100%. The concordance rate was
lower in indolent B-cell lymphoma (66.0%). In conclusion, PET/CT resulted in the upstaging ofeclare no conflicts of interest.
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PET/CT in staging of newly diagnosed lymphoma 131patients with occult extranodal or nodal lesions. A high SUV level can predict aggressive sub-
type of lymphoma and detect aggressive components in indolent lymphoma. PET/CT had a high
PPV for aggressive B-cell lymphoma with diffuse bone marrow FDG uptake and high NPVs for
excluding bone marrow involvement in aggressive B-cell lymphoma and Hodgkin’s lymphoma.
Bone marrow biopsy may be omitted for the above subgroups of patients with medical condi-
tions not suitable for this procedure. For patients with indolent B-cell lymphoma, bone marrow
biopsy is still an indispensable procedure for staging.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Lymphoma is a disease that is characterized by diverse
morphologies, immunophenotypes, cytogenetics, and clin-
ical courses. Precise determinations of the disease stage,
tumor size, and involvement of individual organs are
important when assessing prognostic risks and selecting
appropriate therapies [1]. Computed tomography (CT) and
bone marrow biopsy have been important procedures for
the initial staging and evaluation of treatment response in
patients with lymphomas for decades. CT with intravenous
contrast can sensitively detect lymphadenopathy and organ
involvement with morphologic abnormalities [2,3]. Bone
marrow involvement affects the treatment strategy and
prognosis and is conventionally detected by bone marrow
biopsy [46]. However, there are still limitations to these
examinations that may lead to equivocal results in the
initial staging and clinical decision making. It is difficult to
detect nodal lesions of normal size and hepatic, splenic,
and some occult extranodal involvements using CT. Bone
marrow examination is an invasive diagnostic procedure
that is performed from the iliac crest and allows for the
analysis of only a very limited area. False-negative results
can arise due to unifocal or multifocal bone marrow
involvement in areas other than the iliac crest.
The development of positron emission tomography (PET)
has led to changes in the initial evaluation of lymphoma pa-
tients. PET/CT is a noninvasive, semiquantitativewhole-body
imaging technique that can detectmalignancies through both
anatomical and functional approaches. Cancer cells can be
distinguished from normal cells based on differing metabolic
activities [7,8]. Most tumor cells display increased glycolysis
and hence increased 2-fluorine-18-fluoro-2-deoxy-D-glucose
(FDG) uptake. The standardized uptake value (SUV) is a
semiquantitative parameter that is widely used in PET anal-
ysis and is proportional to the rate of glucose metabolism
within the normal range of serum glucose concentrations.
Previous articles have revealed that PET/CT is emerging as a
useful tool for the evaluation of nodal and extranodal
lymphomatous involvements in lymphoma patients [915].
The purposes of this study were to analyze the results of
PET/CT of newly diagnosed lymphoma patients in Taiwan,
to evaluate the associations between SUV level and
different lymphoma subtypes, and to assess the effect of
PET/CT on initial staging. Additionally, we compared the
diagnoses of lymphomatous bone marrow involvement
based on the results of PET/CT and bone marrow biopsy andthen evaluated the accuracy, sensitivity, and specificity of
PET/CT.
Materials and methods
Patient population
We conducted a retrospective analysis of malignant lym-
phoma patients diagnosed at the Kaohsiung Medical Uni-
versity Hospital, a tertiary medical center in southern
Taiwan, beginning in 2009 after PET/CT imaging was
approved by the National Health Insurance system as an
initial staging tool for newly diagnosed lymphoma patients.
The inclusion criteria were recent diagnosis and histology-
proven Hodgkin’s lymphoma (HL) or non-Hodgkin’s lym-
phoma (NHL). The patients had to be 20 years old or older
and free of other previous or concurrent malignant disease.
All patients underwent PET/CT and bone marrow biopsy as
part of a staging work-up.
All lymphomas were classified based on the 2008 World
Health Organization classification of tumors of hematopoi-
etic and lymphoid tissues. The staging of each patient was
based on the Ann Arbor staging system and was determined
by experts in various professional fields including hema-
tology, radiology, pathology, and nuclear medicine. The
process of the review of the clinical data of the enrolled
patients was approved by an Institutional Review Board
(KMUH-IRB-20130094).
Bone marrow examinations
Bone marrow examination, including aspiration and
trephine biopsy, was performed via the right iliac crest (one
site bone marrow biopsy) by an experienced hematologist
after the procedures had been thoroughly explained to the
patients. The bone marrow specimen was > 2 cm in each
case, and the pathology of each biopsy was peer-reviewed
by experienced pathologists. Immunohistochemical studies
were also incorporated in cases of suspected marrow
involvement. The pathology results were used as the gold
standard of bone marrow involvement (BMI).
18F-FDG PET/CT scanning
All patients received PET/CT according to the protocol
established by our Nuclear Medicine Department. The
132 S.-F. Cho et al.patients fasted for at least 4 hours prior to scanning, and
blood sugar levels were maintained at < 150 mg/dL. After
an intravenous injection of 10 mCi (370 MBq) F-18 FDG, the
patients were asked to lie comfortably to reduce muscular
uptake. Fifty minutes after the administration of FDG, the
patients underwent whole-body imaging with a delicate,
dual-modality PET/CT system (Discovery ST 16, GE Medical
System, Waukesha, Wisconsin, USA). The whole-body CT
scan was acquired using standard parameters. Immediately
following the CT acquisitions, PET scans ranging from the
skull base to the midthigh were acquired. The result of
each PET/CT was carefully reviewed by an experienced
nuclear medicine physician.
FDG accumulation was analyzed semiquantitatively by
calculating the maximal SUV (SUVmax) within the round,
10  10 mm regions of interest (ROIs) within the different
foci that included the biopsy site, the tumorous lesion sites
with the highest FDG accumulations throughout whole-body
image, and three different bone marrow sites (right iliac
crest, sternum, and lumbar spine). The SUV level of each
SUVmax site was collected to evaluate the histologies and
grades. Various cut-off values were used for the prediction
of indolent or aggressive histological subtype.
The determination of bone marrow involvement was
made by a nuclear medicine physician who was blinded to
the pathological diagnoses from the bone marrow biopsy.
According to the CT portion of the PET/CTs, the bone
marrow lesions displayed no obvious cortical bony de-
structions that might indicate bone involvement. A positive
bone marrow involvement result was defined by focally
increased FDG uptake in the bone marrow or diffusely
increased bone marrow uptake with an intensity greater
than that of the liver. A negative result was recorded when
no abnormal FDG uptake was observed. Bone marrow
involvement was classified as focal only, diffuse only, or
both focal and diffuse [16].
Statistical analyses
A receiver operating characteristic (ROC) analysis was used
to evaluate the accuracy. The sensitivity, specificity, posi-
tive predictive value (PPV), and the negative predictive
value (NPV) were also estimated based on the decision
threshold. Comparisons between continuous variables were
made with MannWhitney U-tests. Survival analysis was
completed by using the KaplaneMeier method and
compared using the log-rank test. A p value < 0.05 was
considered to be statically significant. All data were
entered into and analyzed with SPSS 17.0 (SPSS Inc., Chi-
cago, IL, USA) for Windows.
Results
Patient characteristics
The data from 185 newly diagnosed lymphoma patients
were collected for analysis. All patients underwent a bone
marrow biopsy and PET/CT during their initial staging ex-
amination. The median age was 55.8 years (range 2095
years), and there were 108 males (58.4%) and 77 females
(41.6%).Among the patients with NHL, the histology subtypes
included diffuse large B-cell lymphoma (DLBCL, n Z 106),
mantle cell lymphoma (nZ 1), Burkitt’s lymphoma (nZ 2),
follicular lymphoma (FL, n Z 30), and marginal zone lym-
phoma (n Z 17); 13 patients had T-cell NHL (peripheral T
cell lymphoma, n Z 6; angioimmunoblastic T-cell lym-
phoma (AILT), n Z 3; anaplastic large cell lymphoma,
n Z 2; subcutaneous panniculitis-like T-cell lymphoma
(SPTCL), n Z 1; and T-lymphoblastic lymphoma, n Z 1).
Sixteen patients had HL. The characteristics of the patients
and disease statuses are summarized in Table 1.SUV level in the staging of lymphoma
In the staging of the newly diagnosed lymphoma patients,
PET/CT scanning resulted in the upstaging of 17 (9.2%)
patients, including eight with DLBCL, four with follicular
lymphoma, one with marginal zone lymphoma, two with T
cell NHL, and two with HL. These patients were found to
have extranodal involvements that included the liver,
spleen, kidney, and bone. Three of the upstaged patients
were found to have extended lymph node involvement of
normal size (Table 1).
SUVmax data were available for all 185 patients, and the
estimated mean value was 13.22 (range 1.8338.19) (Table
2). Regarding the subgroup analyses, aggressive B-cell
lymphoma had a significantly higher SUV level than did
indolent B-cell lymphoma (16.67, range 2.9638.19 vs.
7.98, range 1.924.39; p < 0.001, Fig. 1). The SUVmax
values of the T-cell NHL and HL were between those of
aggressive and indolent B-cell NHL (9.81, range 1.8323.95
and 11.58, range 6.8618.2, respectively). The relationship
between histology and SUVmax level is shown in Fig. 1.
ROC curve analysis was also used to examine the accu-
racy of SUVmax in differentiating aggressive and indolent B-
cell NHL. The estimated area under the ROC curve was 0.79
(p < 0.001), which suggests that the SUVmax was an
adequate predictor of diagnosis (Fig. 2). Different cut-off
values were used to predict aggressive B-cell NHL (Table
3). At the cut-off value of 10, the sensitivity and speci-
ficity were 72.5% and 70.2%, respectively, and the PPV and
NPV values were 84.9% and 52.4%, respectively. The SUV
levels of the different bone marrow sites (i.e., the sternum,
lumbar spine, and iliac crest) were also analyzed, and no
significant differences were found between the histological
types at these sites (Table 2).PET/CT in the diagnosis of marrow involvement
The results of the bone marrow biopsy and PET/CT were
concordant in 152 patients (82.1%); these results were
concordantly positive in 21 patients and concordantly
negative in 131 patients. The estimated sensitivity, speci-
ficity, PPV, and NPV were 50%, 91.6%, 63.6%, and 86.2%,
respectively (Table 4). Lymphoma subtype analyses
revealed that aggressive B-cell NHL and HL had higher
concordant rates (88.1% and 93.8%, respectively), and
follicular lymphoma and marginal zone lymphoma had
lower concordance rates (66.7% and 64.7%, respectively).
T-cell lymphoma had a concordance rate of 76.9%.
Table 1 Characteristics of the patients.
Histology n Age, mean (range) Stage No. upstaged by PET/CT
1 2 3 4
Total 185 56 (2095) 33 44 42 66 17
Aggressive B-NHL 109 61 (2595) 24 26 22 37 8
DLBCL 106 61 (2595) 22 26 22 36 8
Mantle cell lymphoma 1 53 0 0 0 1 0
Burkitt’s lymphoma 2 54 (5355) 2 0 0 0 0
Indolent B-NHL 47 54 (3281) 7 6 13 21 5
Follicular lymphoma 30 54 (3768) 4 2 10 14 4
Marginal zone lymphoma 17 54 (3281) 3 4 3 7 1
T-NHL 13 56 (3275) 1 2 4 6 2
Peripheral T cell lymphoma 6 (5265) 1 2 2 2 1
AILT 3 58 (4575) 0 0 1 2 1
ALCL 2 64 (5573) 0 0 1 0 0
SPTCL 1 32 0 0 0 1 0
T-lymphoblastic lymphoma 1 46 0 0 0 1 0
Hodgkin’s lymphoma 16 34 (2077) 1 10 3 2 2
AILTZ angioimmunoblastic T-cell lymphoma; ALCLZ anaplastic large cell lymphoma; B-NHLZ B-cell non-Hodgkin’s lymphoma;
DLBCLZ diffuse large B-cell lymphoma; T-NHLZ T-cell non-Hodgkin’s lymphoma; SPTCLZ subcutaneous panniculitis-like T-cell
lymphoma.
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marrow involvement with an accuracy, sensitivity, speci-
ficity, PPV, and NPV of 88%, 70%, 92.1%, 66.7%, and 93.2%,
respectively. HL had an NPV of 100%. In T-cell lymphoma,
PET/CT predicted bone marrow involvement with an ac-
curacy, sensitivity, specificity, PPV, and NPV of 76.9%, 50%,
88.9%, 66.7%, and 80%, respectively. In indolent B-cell NHL,
the accuracy was lower (65.9%). The estimated sensitivity,
specificity, PPV and NPV were 27.8%, 89.7%, 62.5%, and
66.7%, respectively.
The pattern of FDG uptake in the bone marrow was
associated with the concordance rate in aggressive B-cell
NHL. For all six patients with diffuse bone marrow FDG
uptake, the PPV was 100%, and the results of the bone
marrow biopsy were all positive. For the three patients with
focal to diffuse bone marrow FDG uptake, bone marrow
biopsy revealed bone marrow involvement in two patients
and a concordance rate of 66.7%. Among the 12 patients
with focal bone marrow FDG uptake, six patients wereTable 2 The SUV level of different sites of bone marrow of var
Histology SUVmax (mean) (range)
All 13.22 (1.8338.19)
Aggressive B-NHL 16.67 (2.9638.19)
DLBCL 16.56 (2.9638.19)
Mantle cell lymphoma 24.05
Burkitt’s lymphoma 17.12 (4.82 to 29.43)
Indolent B-NHL 7.98 (1.924.39)
Follicular lymphoma 9.46 (2.8324.39)
Marginal zone 5.37 (1.912.63)
T-NHL 9.81 (1.8323.95)
Hodgkin’s lymphoma 11.58 (6.8618.2)
DLBCLZ diffuse large B-cell lymphoma; NHLZ non-Hodgkin’s lymphofound to have bone marrow involvement, which yielded a
concordance rate of 50%.
With respect to the correlation between bone marrow
involvement and prognosis, 36 clinical Stage 4 DLBCL pa-
tients were analyzed. The patients with bone marrow
involvement identified by PET/CT have similar progression-
free survival and overall survival compared with patients
without bone marrow involvement (Fig. 3).Discussion
Whole body PET/CT is a diagnostic imaging tool that com-
bines anatomical and functional studies and has high
sensitivity and specificity in the staging of aggressive NHL
and HL. Previous studies have revealed that different his-
tological types of lymphoma exhibit different FDG uptake,
especially in the differentiation of aggressive and indolent
B-cell lymphoma [17,18]. In the present study, we used SUVious lymphomas.
SUV of bone marrow (mean)
Sternum Lumbar spine Right iliac crest
1.44 1.86 2.41
1.46 1.89 2.54
1.47 1.89 2.54
2.5 2.34 1.42
1.73 2.71 1.17
1.36 1.61 2.31
1.42 1.65 2.38
1.26 1.53 2.19
1.47 2.23 2.58
1.57 2.26 2.94
ma; SUV Z standardized uptake value.
Table 3 Sensitivity, specificity, positive predictive value,
and negative predictive value of different cut-off value
(SUV level) to distinguish patients of aggressive B-cell NHL
from indolent B-cell NHL.
SUV level Aggressive
B-cell NHL,
nZ 109
Indolent
B-cell NHL,
nZ 47
SEN SPE PPV NPV
% % % %
6 94 27 86.2 42.6 77.7 57.1
8 85 19 78.0 59.6 81.7 53.8
10 79 14 72.5 70.2 84.9 52.4
11 73 12 67.0 74.5 85.9 49.3
12 68 9 62.4 80.9 88.3 48.1
14 63 5 57.8 89.4 92.6 47.7
NHLZ non-Hodgkin’s lymphoma; NPVZ negative predictive
value; PPVZ positive predictive value; SENZ sensitivity;
SPEZ specificity; SUVZ standardized uptake value.
Figure 1. Maximal SUV levels across the whole body for
different subtypes of lymphoma. ***p < 0.001. NHL Z non-
Hodgkin’s lymphoma; SUV Z standardized uptake value.
Table 4 Results of BMB and PET/CT in detection of bone
marrow involvement.
134 S.-F. Cho et al.level 10 as the cut-off value to differentiate patients of
aggressive B-cell lymphoma and indolent B-cell NHL
because this value was revealed to provide an adequate
balance of sensitivity and specificity in previous studies
[17,18]. Our study also demonstrated that high SUV level
(SUV > 10) were predictive of aggressive B-cell NHL. How-
ever, 12 patients with follicular lymphoma and two patients
with marginal lymphoma had lesions with high SUV level
(SUVmax > 10). Notably, all of these patients had advanced
lymphoma (10 with Stage 3 and 4 with Stage 4). Addition-
ally, three patients with follicular lymphoma had aggressive
histological types (Grade 3), and one patient experienced a
transformation to aggressive lymphoma (DLBCL). These
results suggest that some of the lesions with high SUV level
on the PET/CT had aggressive histological components in
the patients with indolent lymphoma. More aggressive
treatment or closer monitoring should be considered forFigure 2. Receiver operating characteristic (ROC) curve
demonstrating the discriminative value of the SUV level in
distinguishing patients with aggressive B-cell NHL from patients
with indolent B-cell NHL. The area under the curve was 0.79.
NHL Z non-Hodgkin’s lymphoma; SUV Z standardized uptake
value.such patients because this type of lymphoma is thought to
be more biologically aggressive.
In the staging of newly diagnosed lymphoma patients,
PET/CTscanning resulted in the upstaging of 17 patients, and
most of these upstaged patients were found to have some
extranodal involvement. Modifications to treatment were
also noted and included increased courses of chemotherapy.
Another important issue is the predictive value of PET/
CT for bone marrow involvement. According to a previous
article, approximately 5080% of patients with low-gradeHistology Number PET/CT(+) PET/CT()
BMB(+) BMB() BMB(+) BMB()
All 185 21 12 21 131
Aggressive B-NHL 109 14 7 6 82
DLBCL 106 13 7 6 80
Burkitt’s
lymphoma
2 0 0 0 2
Mantle cell
lymphoma
1 1 0 0 0
Indolent B-NHL 47 5 3 13 26
Follicular
lymphoma
30 4 2 8 16
Marginal zone
lymphoma
17 1 1 5 10
T-cell lymphoma 13 2 1 2 8
Peripheral T-cell
lymphoma
6 1 0 0 5
AILT 3 0 0 1 2
SPTCL 1 0 0 1 0
Anaplastic large
cell lymphoma
2 0 1 0 1
T-lymphoblastic
lymphoma
1 1 0 0 0
Hodgkin’s lymphoma 16 0 1 0 15
DLBCL Z diffuse large B-cell lymphoma; AILT Z angioimmu-
noblastic T-cell lymphoma; SPTCLZ subcutaneous panniculitis-
like T-cell lymphoma; BMB Z bone marrow biopsy.
Figure 3. Survival analysis of 36 Stage 4 DLBCL patients with
or without bone marrow involvement identified by PET/CT.
CT Z computed tomography; NR Z not reached;
PET Z positron emission tomography.
PET/CT in staging of newly diagnosed lymphoma 135NHL, 2540% of patients with high-grade NHL, and 514%
of patients with HL exhibit bone marrow involvement at
diagnosis. [19] Some studies have revealed that PET/CT can
identify bone marrow lymphomatous involvement if it is
evaluated cautiously [18,20,21]. In our study, there was no
significant difference in the bone marrow SUV level be-
tween the patients with and without bone marrow
lymphomatous involvement. The SUV value of lymphoma
involving the marrow may not be affected or elevated
because of scattered distribution of lymphoma cells,
although these lymphoma cells can be observed micro-
scopically. These results support the notion that the
determination of bone marrow disease relies on the
“contrast” that results from focal increases in FDG avidity
rather than the SUV level.
PET/CT can detect bone marrow involvement in patients
with aggressive B-cell NHL if diffuse bone marrow FDG up-
take is noted. However, diffusely increased FDG avidity
may also be due to the reactivation of bone marrow caused
by inflammation or active hematopoiesis, which highlightsthe importance of the interpretation of PET/CT results by
an experienced expert.
Among the patients with aggressive B-cell NHL, we
observed six patients with positive bone marrow biopsy
results and negative PET/CT results. Interestingly, all of
these patients had advanced diseases (Stage 4), huge pri-
mary lesions (>10 cm), disseminated nodal and extranodal
diseases, or high proliferation index (Ki-67 > 70%) according
to the pathologic examinations. The average whole-body
SUVmax (mainly in the primary lesions) of these patients
was relatively high (SUV > 15). We speculate that
competitive FDG uptake from the larger main tumor with
high proliferation activity resulted in relatively lower FDG
uptake in the bone marrow compared to that of patients
with less tumor burden [22,23], which would lead to false-
negative results and underdiagnosis based on FDG PET/CT
evaluations (Fig. 4). Discordant results were also noted in
the patients with indolent B-cell NHL that involved positive
bone marrow biopsy and negative PET/CT results. A
possible explanation for this discordance is that the indo-
lent biological activity caused FDG avidity in the bone
marrow disease that was judged to be a reactive change or
even a normal marrow appearance because no foci with
salient “lesion-to-background” differences were detected.
Additionally, some patients were determined to have bone
marrow involvement based on the PET/CT despite negative
bone marrow results. This discordance suggests that some
focal lesions will be missed if patients only undergo bone
marrow examinations.
Our results revealed a high concordance rate in the
prediction of HL bone marrow involvement. In patients at
Stages 1 and 2, the PET/CT and bone marrow biopsy results
were concordant. Only one Stage 4 patient was observed to
have bone marrow involvement based on the PET/CT and a
negative bone marrow examination. Additionally, the high
NPV (100%) indicated that such patients do not require bone
marrow biopsy if the PET/CT results are negative for bone
marrow involvement. In terms of T-cell lymphoma, our
concordance rate was lower than that reported in another
study [18], which may be due to the rarity and heteroge-
neity of the histological subtypes in our study.
Our study analyzed the correlation between PET/CT
prediction on bone marrow involvement and clinical
outcome. In clinical Stage 4 DLBCL patients, patients with
bone marrow involvement determined by PET/CT have
similar outcomes compared with patients without bone
marrow involvement. This result was concordant with
another previous study [24]. For patients with other sub-
types of lymphoma, a study enrolling more cases may pro-
vide more impactful information.
In conclusion, we demonstrated that PET/CT is a sensi-
tive and accurate diagnostic and staging tool for patients
with lymphoma. PET/CT had a high PPV for aggressive B-
cell NHL with diffuse bone marrow FDG uptake and a high
NPV for the exclusion of bone marrow involvement in
aggressive B-cell NHL and HL. These findings indicated that
PET/CT should replace bone marrow biopsy for the above
subgroup if the patients’ medical conditions are not suit-
able for biopsy. For patients with indolent B-cell lym-
phoma, bone marrow biopsy still plays an indispensable role
in the staging work-up.
Figure 4. A patient with a huge cutaneous diffuse large B-cell lymphoma on the back. The bone marrow examination was
positive for lymphomatous involvement, but the CT and PET scan revealed no obvious FDG avidity in the bone marrow in the sagittal
(Panels A and B) or transverse views (Panels C and D). Panels A and C: Computed tomography. Panels B and D: PET scan.
CT Z computed tomography; PET Z positron emission tomography.
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